PVT201
/ Parvus Therap
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
November 02, 2025
A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, andnPharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in primary biliary cholangitis/primary sclerosing cholangitis patients.
(ANZCTR)
- P1 | N=6 | Withdrawn | Sponsor: Parvus Therapeutics, Inc. | Not yet recruiting ➔ Withdrawn
First-in-human • Trial withdrawal • Hepatology • Immunology • Primary Biliary Cholangitis
August 20, 2025
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Parvus Therapeutics, Inc. | Recruiting ➔ Completed
Trial completion • Hepatology • Immunology • Primary Biliary Cholangitis
June 27, 2025
A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects.
(ANZCTR)
- P1 | N=24 | Completed | Sponsor: Parvus Therapeutics, Inc. | Not yet recruiting ➔ Completed | N=36 ➔ 24
Enrollment change • Trial completion • Trial initiation date • Hepatology • Immunology • Primary Biliary Cholangitis
May 28, 2025
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Parvus Therapeutics, Inc. | Trial completion date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2025
Trial completion date • Trial primary completion date • Hepatology • Immunology • Primary Biliary Cholangitis
January 29, 2025
Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Parvus Therapeutics, Inc.
New P1 trial • Hepatology • Immunology • Primary Biliary Cholangitis
August 09, 2024
A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 Following Randomized, Double-blind, Placebo-controlled Single Ascending Doses in Healthy Subjects
(ANZCTR)
- P1 | N=36 | Not yet recruiting | Sponsor: Parvus Therapeutics, Inc.
New P1 trial • Hepatology • Immunology • Primary Biliary Cholangitis
1 to 6
Of
6
Go to page
1